Related Experiment Video
Updated: Sep 13, 2025
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Immune Checkpoint Inhibitors in Kidney Transplant Recipients: A French Multicenter Retrospective Cohort Study
Tristan Legris1, Marion Sallée1, Xavier Charmetant2
1Department of Nephrology and Kidney Transplantation, APHM, Conception University Hospital, Marseille, France.
Background:
Kidney transplant recipients (KTRs) are at elevated risk of malignancy. Data on the safety and efficacy of immune checkpoint inhibitors (ICIs) in this population remain limited. We aimed to reassess the benefit-risk profile of ICI therapy in KTRs using a multicenter cohort, in the recent era.
Methods:
We conducted a retrospective cohort study of all KTRs treated with ICIs for advanced or metastatic cancer, across 6 transplant centers. We evaluated cancer response, acute rejection (AR) incidence, graft survival, and patient survival.
Results:
From 2015 to 2024, 34 KTRs were analyzed. The most common cancers were cutaneous (56%) and non-small cell lung cancer (32%). Pembrolizumab was the most used ICI (53%). The objective response rate was 38%, with a median progression-free survival of 5.5 mo and an overall survival of 10.7 mo. Biopsy-proven AR occurred in 26.5% of patients, at a median time of 52 d after ICI start. All rejection episodes involved T cells, and one-third showed additional humoral features. No clinical predictors of AR were identified. Among all patients, 29% had a favorable outcome (tumor response without ICI-induced graft loss), 12% experienced a tumor response with graft loss, 59% had progression disease without graft loss, and 3% experienced the worst outcome (progression disease with graft loss).
Conclusions:
Our study suggests that ICI therapy is a viable option for KTRs with poor-prognosis cancers, demonstrating a 38% tumor response rate and a lower incidence of graft loss (15%) compared with previously reported rates. Prospective studies are needed to optimize the use of ICI in KTRs.
Insights
Immune checkpoint inhibitors (ICIs) show promise for kidney transplant recipients (KTRs) with advanced cancers, offering a 38% response rate. This therapy presents a viable option with a manageable risk of graft loss.
Area of Science:
- Oncology
- Nephrology
- Immunology
Background:
- Kidney transplant recipients (KTRs) face a higher risk of developing cancer.
- Limited data exist on the safety and effectiveness of immune checkpoint inhibitors (ICIs) in KTRs.
- This study reassesses the benefit-risk profile of ICI therapy in KTRs.
Purpose of the Study:
- To evaluate the efficacy and safety of immune checkpoint inhibitors (ICIs) in kidney transplant recipients (KTRs).
- To determine the cancer response, acute rejection (AR) incidence, and survival outcomes in KTRs treated with ICIs.
Main Methods:
- Retrospective cohort study across 6 transplant centers.
- Analysis of KTRs treated with ICIs for advanced or metastatic cancer from 2015 to 2024.
- Evaluation of cancer response, AR, graft survival, and patient survival.
Main Results:
- 38% objective response rate observed in 34 KTRs, with median progression-free survival of 5.5 months.
- Acute rejection (AR) occurred in 26.5% of patients, primarily T-cell mediated.
- Favorable outcomes (tumor response without graft loss) seen in 29% of patients; 15% experienced graft loss.
Conclusions:
- ICI therapy is a viable option for KTRs with poor-prognosis cancers.
- Observed tumor response rate of 38% and a lower graft loss incidence (15%) than previously reported.
- Further prospective studies are recommended to optimize ICI use in KTRs.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:16Kidney Transplant III: Nursing Management
01:26Kidney Transplant II: Surgical Procedure
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:22Acute Kidney Injury I: Introduction
01:29Acute Kidney Injury II: Pathophysiology